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During the second half of the twentieth century,
researchers have been focused on breaking down science
into small pieces, and in doing so have learned that
understanding the small pieces does not necessarily
translate into a greater understanding of the whole. Sys-
tems biology has emerged as a way of understanding
these systems in total, but requires scientists to work
through complexity to arrive at a greater understanding.
To understand the fundamental biology of TB, scientists
must first understand the biology of latent TB: why the
bacteria are able to resist the host’s ability to eradicate
them over a long period of time. The commonly-used
definition of latent TB—antigen-specific T-cell response
without clinical symptoms—is very broad and may in
fact lead us away from the consideration that latent TB
may not be the same in every patient. Does everyone
infected with latent TB harbor viable bacteria? Where
are these bacteria in the body and what are they doing?
As part of the Grand Challenges in Global Health Pro-
gram, a Gates Foundation-funded initiative to develop
drugs for latent TB, our team is working with a hypoxia
model, based on the idea that the bacteria encounters
an environment (hypoxia) in the host which is hostile.
In response, the bacteria may switch to a slowly-repli-
cating persistent phenotype that makes them more
drug-tolerant. We are also using live-imaging to study
lesions in active latent TB in both humans and primates
to identify what the bacteria are doing in different types
of lesions, why some bacteria are immunologically active
and others dormant.
Based on our findings to date, biomarkers in addition
to T-cell response must be identified in order to develop
a better understanding of what is happening in patients
with latent TB. We hypothesize that latent TB encom-
passes a broad spectrum of responses in patients, from
the infection being eliminated without priming antigen-
specific T cells, through the infection being controlled
with some bacteria persisting but reduced replication, to
some bacterial replication being maintained at a subcli-
nical immune response. Our theory is that the infection
in patients with latent TB can move along this spectrum
over the course of time. With additional biomarkers—
such as ones measuring bacterial load or cell surface
markers—subsets of patients can be identified who
would benefit from preventive therapy, making this a
more realistic and effective approach in the goal of
eliminating TB by 2050.
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